Keywords: novartis, xolair, cuts, severe, exacerbations, asthma, patients

Novartis' Xolair cuts severe exacerbations in asthma patients 44%, study shows

Article | 06 June 2005

Print This

Data from a clinical study, presented at the centenary congress of the American Thoracic Society in San Diego, California, demonstrate ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in